Efficacy of Dacomitinib

Dacomitinib (Dacomitinib) is a potent, irreversible, highly selective 2G EGFR-TKI that inhibits signaling from heterodimers and homodimers of all members of the human EGFR family. In the ARCHER 1050 trial, dacomitinib showed a significantly better progression-free survival (PFS) benefit than gefitinib, providing the basis for its use as a standard first-line option for EGFR-positive advanced non-small cell lung cancer (NSCLC).

A case series study of 14 patients showed that dacomitinib is also effective in central nervous system (CNS) metastasis of EGFR-positive non-small cell lung cancer. 56.3% of patients had confirmed partial response, 90.6% of the disease was under control, the median PFS was 10.3 months, and the median OS was 36.5 months. In addition, dacomitinib has potential application in patients carrying rare mutations, and dacomitinib has good late-stage efficacy in patients with non-small cell lung cancer carrying uncommonEGFR mutations.

The original drug of dacomitinib has been launched in China and has entered the scope of Class B medical insurance. The price of the common specification 15mg*30 tablets per box may be more than 1,000 yuan; the European version of dacomitiniboriginal drug sold overseas, the specification 45mg*30 tablets may be more than 20,000 yuan per box (the price may fluctuate due to exchange rates). Currently, there are cheaper generic drugs of dacomitinib sold overseas. Their pharmaceutical ingredients are basically the same as those of the original drugs sold domestically and abroad. For example, the price of 45mg*30 tablets produced by a Lao pharmaceutical factory may be around a few hundred yuan per box (the price may fluctuate due to exchange rate effects).